Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | RXRA | P19793 | 1/20 | 0.48 |
| ▸ | RXRB | P28702 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.47 |
| ▸ | ERN1 | O75460 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.46 |
| ▸ | DHFR | P00374 | 2/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL198917 | 0.88 | KDM4E (0.59) | KDM4ETSHRBACE1SLC13A5SMN1; SMN2 | |
| SCHEMBL1337788 | 0.86 | TP53 (0.65) | KDM4ETSHRBACE1SLC13A5TAAR1 | |
| SCHEMBL15473215 | 0.86 | KMT2A (0.57) | KDM4EBACE1SLC13A5SMN1; SMN2RXRA | |
| SCHEMBL2574296 | 0.85 | SLC13A5 (0.54) | KDM4EBACE1SLC13A5SMN1; SMN2TAAR1 | |
| SCHEMBL5380417 | 0.82 | RAB9A (0.60) | KDM4ETSHRSMN1; SMN2KMT2ATP53 | |
| SCHEMBL1336605 | 0.81 | KDM4E (0.52) | KDM4ETSHRBACE1SLC13A5SMN1; SMN2 | |
| SCHEMBL8396365 | 0.81 | TSHR (0.58) | TSHRSMN1; SMN2CYP3A4 | |
| SCHEMBL16378738 | 0.81 | MAPT (0.53) | KDM4EBACE1SLC13A5SMN1; SMN2RXRA | |
| SCHEMBL993788 | 0.80 | TSHR (0.77) | KDM4ETSHRKMT2ATP53CYP3A4 | |
| SCHEMBL533192 | 0.80 | KDM4E (0.50) | KDM4ETSHRBACE1SLC13A5SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9758474-B2 | Immunomodulator and anti-inflammatory compounds | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2017-09-12 | — | — | US | disclosed |
| US-20140220050-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | INCOZEN THERAPEUTICS PVT. LTD. (CH) | 2014-08-07 | — | — | US | disclosed |
| US-20110275603-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | RHIZEN PHARMACEUTICALS SA (FR) | 2011-11-10 | — | — | US | disclosed |
| EP-0789577-B1 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORP (US) | 2003-03-12 | — | — | EP | disclosed |
| EP-0671928-B1 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORP (US) | 2002-11-27 | — | — | EP | disclosed |
| EP-1258492-A1 | N-substituted oligomers and methods for their synthesis, e.g. polyglycine bearing nucleic acid bases | CHIRON CORPORATION (US) | 2002-11-20 | — | — | EP | disclosed |
| US-5977301-A | AUTOMATED AND EFFICIENT SYNTHESIS BY REACTING SOLID SUPPORT BOUND AMINE WITH AN ACYLATING SUBMONOMER TO PRODUCE A SOLID SUPPORT-BOUND AMIDE WHICH CAN BE FURTHER REACTED; ONLY REACTIVE SIDE CHAINS NEED PROTECTED | CHIRON CORPORATION (US) | 1999-11-02 | — | — | US | disclosed |
| US-5877278-A | SOLID PHASE SYNTHESIS USING TWO SUBMONOMERS-AN ACYLATING AGENT, E.G. A HALOACETIC ACID, AND A PRIMARY AMINE; CYCLIZATION TO PRODUCE MIMETICS OF DRUGS; ELIMINATION OF THE NECESSITY OF PROTECTION GROUPS | CHIRON CORPORATION (US) | 1999-03-02 | — | — | US | disclosed |
| US-5831005-A | ACYLATION, NUCLEOPHILIC DISPLACEMENT CYCLES | CHIRON CORPORATION (US) | 1998-11-03 | — | — | US | disclosed |
| EP-0789577-A4 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORP (US) | 1998-07-22 | — | — | EP | disclosed |
| EP-0789577-A1 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORPORATION (US) | 1997-08-20 | — | — | EP | disclosed |
| EP-0671928-A4 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS. | CHIRON CORP (US) | 1997-04-23 | — | — | EP | disclosed |
| WO-1996040202-A1 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5480871-A | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | CHIRON CORPORATION (US) | 1996-01-02 | — | — | US | disclosed |
| EP-0671928-A1 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORPORATION (US) | 1995-09-20 | — | — | EP | disclosed |
| US-5447916-A | Hypotensive agents | CHIRON CORPORATION (US) | 1995-09-05 | — | — | US | disclosed |
| WO-1994006451-A1 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORPORATION (US) | 1994-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140220050-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | DHODH, DLD, DHFR | KDM4E 1861/4885TSHR 4789/4885BACE1 4104/4885 |
| US-20110275603-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | DHODH, DLD, DHFR | KDM4E 1861/4885TSHR 4789/4885BACE1 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.